Yury Gezentsvey

This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Pramana Pharmaceuticals Inc.. Active years: 2021-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yury Gezentsvey. Retrieved from https://idiyas.com/inventor/yury-gezentsvey

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)

Company Filing History:

2 out of 3

Pramana Pharmaceuticals Inc.

patents

Years Active: 2021-2024

Loading Chart...

2 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12037328 - Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of G protein-coupled receptor 119 (2024-07-16),

2. 10906894 - Compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of g protein-coupled receptor 119 (2021-02-02),

Title: Yury Gezentsvey: Innovator in Pharmaceutical Compounds

Introduction

Yury Gezentsvey is a notable inventor based in Moscow, Russia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific receptors related to metabolic disorders. With a total of 2 patents, his work is paving the way for potential treatments for various health conditions.

Latest Patents

Yury Gezentsvey's latest patents focus on compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide, and benzo[d][1,3]oxathiole 3,3-dioxide. These compounds are designed as agonists of G protein-coupled receptor 119. The patents detail methods and uses related to these compounds, particularly in the treatment of diseases associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders.

Career Highlights

Yury is currently associated with Pramana Pharmaceuticals Inc., where he continues to innovate and develop new pharmaceutical solutions. His expertise in the field has led to advancements that could significantly impact the treatment of metabolic disorders.

Collaborations

Yury has collaborated with notable colleagues, including Tarek Suhayl Mansour and Mikhail Yudin. These partnerships enhance the research and development efforts within the pharmaceutical industry.

Conclusion

Yury Gezentsvey's contributions to pharmaceutical innovations demonstrate his commitment to improving health outcomes through targeted therapies. His work continues to inspire advancements in the treatment of metabolic disorders.

Profile summary based on public USPTO records.